explored the effects of radiotherapy on the upregulation of MHC class II molecules and demonstrated that radiotherapy‐exposed neoantigens on CD4+ T cells improved tumor control, which supports the notion of enhanced antigen presentation capacity.[36] Upon exposure to antigens, cDCs process and present antigenic peptides bound to MHC class II molecules on their cell surface.[37] The upregulation of the MHC protein complex binding signaling pathway in cDCs indicates increased intracellular signaling events associated with antigen presentation. Here, CD4 is linked to neoplasm.